N@N

Dr. Reddya?s provides update on the fexofenadine-pseudoephedrine 24 hour Preliminary Injunction hearing

^{Published on 2010-06-12 08:45:09 - Market Wire}
 

HYDERABAD, India--([ BUSINESS WIRE ])--Dr. Reddya™s Laboratories (NYSE: RDY) announced today that the U.S. District Court of New Jersey has granted sanofi-aventis and Albany Molecular Researcha™s motion for a Preliminary Injunction. The motion is related to Dr. Reddya™s abbreviated new drug application to market its generic version of Allegra D24® (fexofenadine hydrochloride / pseudoephedrine hydrochloride 180 mg / 240 mg extended release tablet).

Dr. Reddya™s strongly disagrees with the Courta™s decision and intends to appeal.

^®Allegra D24 is a registered trademark of sanofi-aventis.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddya™s

Established in 1984, Dr. Reddya™s Laboratories (NYSE: RDY) is an emerging global pharmaceutical company. We fulfill our purpose of providing affordable and innovative medicines through three core businesses: Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Our products are marketed globally, with a focus on India, US, UK, Germany and Russia.

[ www.drreddys.com ]